Table 1.
(A) The IC50 of R.S., C.P., C.C.-AgNPs, and (B) the Mean Inhibition Zone of R.S., C.P., C.C.-AgNPs
| (A) Anticancer Activity | ||||||||
| Name |
KAIMRC2 IC50 (μg/mL) |
KAIMRC2 Standard Deviation of the Residuals (Sy.x) |
MDA-MB231 IC50 (μg/mL) |
MDA-MB231 Standard Deviation of the Residuals (Sy.x) |
MCF-7 IC50 (μg/mL) |
MCF-7 Standard Deviation of the Residuals (Sy.x) |
MCF-10A IC50 (μg/mL) |
MCF-10A Standard Deviation of the Residuals (Sy.x) |
| R.S.-AgNPs | 204.4 | ± 6.51 | 154.7 | ± 7.76 | 168.1 | ± 5.62 | 460.2 | ± 13.89 |
| C.P.-AgNPs | 140.8 | ± 4.71 | 175.9 | ± 4.98 | 121.2 | ± 5.82 | 303.7 | ± 10.24 |
| C.C.-AgNPs | 135.1 | ± 3.87 | 173.7 | ± 7.44 | 163.5 | ± 6.53 | 429.1 | ± 12.20 |
| Mitoxantrone | 1.30 | ± 12.62 | 1.67 | ± 11.92 | 1.27 | ± 9.11 | 2.06 | ± 10.05 |
| (B) Antibacterial Activity | ||||||||
| Name | S. aureus | E. coli | ||||||
|
Mean Inhibition Zone (mm) |
Standard Deviation (Sy.x) |
Mean Inhibition Zone (mm) |
Standard Deviation (Sy.x) |
|||||
| R.S.-AgNPs | 19.00 | ± 0.82 | 20.25 | ± 0.50 | ||||
| C.P.-AgNPs | 18.50 | ± 0.58 | 17.25 | ± 0.50 | ||||
| C.C.-AgNPs | 20.50 | ± 0.58 | 17.50 | ± 0.58 | ||||
| Ampicillin | 13.25 | ± 0.50 | 12.50 | ± 0.58 | ||||